Evidence map›Paper›PMID 35770002›Full record

ArticleFrontiers in medicine2022

Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients With Inflammatory Rheumatic Diseases in Portugal-A Multicenter, Nationwide Study.

Ana Rita Cruz-Machado, Sofia C Barreira, Matilde Bandeira, Marc Veldhoen, Andreia Gomes, Marta Serrano, Catarina Duarte, Maria Rato, Bruno Miguel Fernandes, Salomé Garcia and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 12 institutions in 1 country.

Ana Rita Cruz-MachadoRheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET), Lisbon, Portugal.
Sofia C BarreiraRheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET), Lisbon, Portugal.
Matilde BandeiraRheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET), Lisbon, Portugal.
Marc VeldhoenInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Andreia GomesInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Marta SerranoInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Catarina DuarteRheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET), Lisbon, Portugal.
Maria RatoRheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal.
Bruno Miguel FernandesRheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal.
Salomé GarciaRheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal.
Filipe PinheiroRheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal.
Miguel BernardesRheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal.
Nathalie MadeiraRheumatology Department, Instituto Português de Reumatologia, Lisbon, Portugal.
Cláudia MiguelRheumatology Department, Instituto Português de Reumatologia, Lisbon, Portugal.
Rita TorresRheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal.
Ana Bento SilvaRheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal.
Jorge PestanaRheumatology Department, Hospital Garcia de Orta, Almada, Portugal.
Diogo AlmeidaRheumatology Department, Hospital de Braga, Braga, Portugal.
Carolina MazedaRheumatology Department, Centro Hospitalar do Baixo Vouga and iBiMED, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal.
Filipe Cunha SantosLocal Health Unit of Guarda, Rheumatology Department, Guarda, Portugal.
Patrícia PintoRheumatology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
Marlene SousaRheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Hugo ParenteRheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal.
Graça SequeiraRheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal.
Maria José SantosRheumatology Department, Hospital Garcia de Orta, Almada, Portugal.
João Eurico FonsecaRheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET), Lisbon, Portugal.
Vasco C RomãoRheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET), Lisbon, Portugal.
University of Lisbon · PTHospital de São João · PTHospital de Egas Moniz · PTHospital Garcia de Orta · PTInstituto Português de Malacologia · PTAdministração Regional de Saúde de Lisboa e Vale do Tejo · PTAlgarve Biomedical Center · PTCentro Hospitalar de Vila Nova de Gaia · PTCentro Hospitalar do Baixo Vouga · PTHospitais da Universidade de Coimbra · PTHospital Braga · PTInstituto Politécnico da Guarda · PT

Funding

NIAID NIH HHS HHSN272201400008C
6 · The paper itself

Abstract

Objective: To identify risk factors for SARS-CoV-2 infection and for severe/critical COVID-19, and to assess the humoral response after COVID-19 in these patients. Methods: Nationwide study of adult patients with inflammatory RMDs prospectively followed in the Rheumatic Diseases Portuguese Register-Reuma.pt-during the first 6 months of the pandemic. We compared patients with COVID-19 with those who did not develop the disease and patients with mild/moderate disease with those exhibiting severe/critical COVID-19. IgG antibodies against SARS-CoV-2 were measured ≥3 months after infection and results were compared with matched controls. Results: 162 cases of COVID-19 were registered in a total of 6,363 appointments. Patients treated with TNF inhibitors (TNFi; OR = 0.160, 95% CI 0.099-0.260, Conclusions: TNFi and tocilizumab reduced the risk of infection by SARS-CoV-2. Treatment with TNFi also tended to reduce rates of severe disease and seroconversion. Older age, general comorbidities and rituximab were associated with increased risk for infection and worse prognosis, in line with previous reports. Most patients with RMDs developed a proper antibody response after COVID-19, particularly if they had symptomatic disease.

Indexed as

antibody responseCOVID-19inflammatory rheumatic diseasesSARS-CoV-2seroconversion

Identifiers

PMID35770002
PMCPMC9234392
OpenAlexW4285740503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.